Capital Market Observer: In 2024, Pharmaceutical Issuers Hold Great Promise for the Long Term.

JAKARTA, January 18, 2024 – The pharmaceutical sector remains attractive in 2024, including the stocks of issuers in that sector. Despite numerous challenges, there are also ample opportunities. The continuous growth of pharmaceutical companies in Indonesia, both in terms of drug production and healthcare equipment, including traditional medicine, contributes to the bright outlook for the pharmaceutical market this year.

According to capital market observer Haryajid Ramelan, the population factor in Indonesia, with 270 million people, and the global population of 8 billion, represent a highly potential market both currently and in the future. In his view, meeting the demand for drugs domestically is already significant, especially considering other countries like Africa and the Middle East.

"Innovations are needed to expand into countries with high populations and economic growth, not only in developing countries. This sector still has high and stable growth, and demand conditions are quite good, especially among those with stable incomes," he stated in Jakarta (15/1).

The Chief Executive Officer of the Capital Market Profession Certification Institute (LSPPM) emphasized that innovation is crucial for pharmaceutical companies. He cited the latest healthcare inventions and the development of drugs to address the high demand for various diseases worldwide.

"Applying artificial intelligence (AI) and blockchain technology will foster the pharmaceutical sector," he added.

Despite the high cost, the development of new drugs could present significant opportunities if pharmaceutical companies enter this field.

"Companies can also collaborate with academia," he added.

From an investment perspective, this sector can also provide dividends, especially for long-term portfolios.

"(Pharmaceutical) issuers are still very attractive, promising, and can be held for the long term. Overall, this sector is still viewed positively, with high potential, so it's reasonable that many investors are considering collecting them."

Separately, the CEO of PT Phapros Tbk, David Sidjabat, stated that in 2024, the company will continue to partner with various institutions to innovate and create the latest medical devices and drugs.

"We have collaborated with several universities and research institutions to develop innovative products. On the other hand, we are also internally developing innovative dosage forms, so the variety of Phapros products will continue to expand. In addition, the export plan for 2024 is still on schedule. We are optimistic that this year, Phapros' growth will remain positive," he revealed.

PT Phapros Tbk, a part of the State-Owned Enterprises pharmaceutical holding, is widely known for its Antimo products. As an Islamic issuer, Phapros' financial performance and the long-term movement of its stock prices are quite appealing to investors.

"Even in the first quarter, we will continue to deliver our best performance, which will also be enjoyed by investors," he concluded.